Metraipolis › archive › dc_4ebf9bada4a4

Real-World Effectiveness of Tezepelumab in Severe Asthma: A Comparative Analysis of High and Low T2 Phenotypes — Europe PMC PMID:41893035

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41893035
DOI
10.3390/jpm16030167
License (as archived)
solo-consultazione
Archived
2026-11-04T06:46:50.910Z
SHA-256 of the archived text
781f54342ddab046c943530ce984ed62f87aeca6bc5b5530fac61bc1343e4d1f
Stable URL of this page
https://metraipolis.com/documento/dc_4ebf9bada4a4

How to cite

Real-World Effectiveness of Tezepelumab in Severe Asthma: A Comparative Analysis of High and Low T2 Phenotypes — Europe PMC PMID:41893035 — Europe PMC (en), https://europepmc.org/article/MED/41893035 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4ebf9bada4a4 (Metraipolis archive dc_4ebf9bada4a4, sha256 781f54342ddab046c943530ce984ed62f87aeca6bc5b5530fac61bc1343e4d1f)
BibTeX
@misc{dc4ebf9bada4a4,
  title = {Real-World Effectiveness of Tezepelumab in Severe Asthma: A Comparative Analysis of High and Low T2 Phenotypes — Europe PMC PMID:41893035},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41893035},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4ebf9bada4a4; sha256 781f54342ddab046c943530ce984ed62f87aeca6bc5b5530fac61bc1343e4d1f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41893035. Agents can read the archived copy with the MCP tool read_document.